共 50 条
- [21] LIVER ENZYMES REDUCTIONS FROM BASELINE OVER TIME IN RESMETIROM TREATED PATIENTS IN A PHASE 3 STUDY, MAESTRO-NASHHEPATOLOGY, 2024, 80Baum, SethTaub, RebeccaLabriola, DominicAlkhouri, NaimNoureddin, Mazen
- [22] COST-EFFECTIVENESS ANALYSIS OF RESMETIROM FOR THE TREATMENT OF ADULTS WITH NONCIRRHOTIC NASH AND MODERATE-TO-ADVANCED LIVER FIBROSIS IN THE US: INTEGRATING THE DUAL NASH RESOLUTION AND FIBROSIS IMPROVEMENT ENDPOINTSVALUE IN HEALTH, 2024, 27 (12) : S122 - S122Kim, Y.Smith, Z.Mitchell, D.Johnson, S.
- [23] Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B: Protocol for a Phase 3 Randomized TrialJOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2025,Cai, XiaoboQu, YinXie, WenWang, YanbinZhao, MengyuZhang, LingLuo, YingYin, PingCheng, JunLu, Lungen
- [24] A Phase I Randomized, Controlled, Clinical Trial of Valganciclovir in Idiopathic Pulmonary FibrosisANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (08) : 1291 - 1297Blackwell, Timothy S.Hewlett, Justin C.Mason, Wendi R.Martin, SusanDel Greco, JamesDing, GuixiaoWu, PingshengLancaster, Lisa H.Loyd, James E.Dudenhofer, Rosemarie B.Salisbury, Margaret L.Kropski, Jonathan A.
- [25] Health-Related Quality of Life (HRQL) assessments in a 52-Week, double-blind, randomized, placebo-controlled phase 3 study of Resmetirom (MGL-3196) in patients with non-alcoholic steatohepatitis (NASH) and fibrosis (MAESTRO-NASH)JOURNAL OF HEPATOLOGY, 2024, 80 : S465 - S465Younossi, ZobairStepanova, MariaRacila, AndreiHenry, LindaMiller, KeithLabriola, DominicTaub, RebeccaNader, Fatema
- [26] Analyses of fibrosis biomarkers PRO-C3 and ELF in resmetirom treated patients from MAESTRO-NASH, a 52 Week NASH/MASH serial liver biopsy studyJOURNAL OF HEPATOLOGY, 2024, 80 : S509 - S509Anstee, Quentin M.Schattenberg, Jorn M.Taub, RebeccaLabriola, DominicZhang, HangHennan, Jim
- [27] STEATOSIS AND FIBROSIS MEASURED AS CONTINUOUS VARIABLES ON PAIRED, SERIAL LIVER BIOPSIES IN THE RESMETIROM (MGL-3196) 36-WEEK PHASE 2 NASH STUDYHEPATOLOGY, 2019, 70 : 1263A - 1263AHarrison, Stephen A.Tai, DeanRen, Ya-YunTaub, Rebecca A.Bashir, Mustafa
- [28] Oltipraz therapy in patients with liver fibrosis or cirrhosis: a randomized, double-blind, placebo-controlled phase II trialJOURNAL OF PHARMACY AND PHARMACOLOGY, 2011, 63 (05) : 627 - 635Kim, Sang GeonKim, Young MiChoi, Jong YoungHan, Joon-YeolJang, Jeong WonCho, Se-HyunUm, Soon HoChon, Chae YoonLee, Dong HooJang, Ja-JuneYu, EunsilLee, Young Sok
- [29] BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary FibrosisAMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (01) : 92 - 99King, Talmadge E., Jr.Brown, Kevin K.Raghu, Ganeshdu Bois, Roland M.Lynch, David A.Martinez, FernandoValeyre, DominiqueLeconte, IsabelleMorganti, AdeleRoux, SebastienBehr, Juergen
- [30] A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHNEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (17): : 1547 - 1558Francque, Sven M.Bedossa, PierreRatziu, VladAnstee, Quentin M.Bugianesi, ElisabettaSanyal, Arun J.Loomba, RohitHarrison, Stephen A.Balabanska, RozalinaMateva, LyudmilaLanthier, NicolasAlkhouri, NaimMoreno, ChristopheSchattenberg, Jorn M.Stefanova-Petrova, DianaVonghia, LuisaRouzier, RegineGuillaume, MaevaHodge, AlexanderRomero-Gomez, ManuelHuot-Marchand, PhilippeBaudin, MartineRichard, Marie-PauleAbitbol, Jean-LouisBroqua, PierreJunien, Jean-LouisAbdelmalek, Manal F.